Review of common adverse effects of selected antiarrhythmic drugs

Critical Care Nursing Quarterly

Volumn 22, Issue 4, 2000, Pages 23-38

  Wooten, James M ^a   Earnest, James ^b   Reyes, Jackie ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b Clinical Cardiovascular Associates   (United States)

^c Trinity Lutheran Hospital   (United States)

Author keywords

Adverse drug effects; Antiarrythmic drug; Arrhythmia; Cardiovascular drugs

Indexed keywords

ADENOSINE; ALUMINUM HYDROXIDE; AMINOTRANSFERASE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTINUCLEAR ANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; COLESTYRAMINE; DIGITALIS; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; DISOPYRAMIDE; FLECAINIDE; IBUTILIDE; LIDOCAINE; MAGNESIUM; MEXILETINE; MORACIZINE; POTASSIUM; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; THEOPHYLLINE; TOCAINIDE; UNINDEXED DRUG; WARFARIN;

BLOOD TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG CONTRAINDICATION; ELECTROCARDIOGRAPHY; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LUNG TOXICITY; NEUROTOXICITY; REVIEW; SKIN MANIFESTATION;

EID: 0033974597     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200002000-00004     Document Type: Review

References (32)

1. Young LR, Wurtzbacher JD, Blankenship CS. Adverse drug reactions: A review for Healthcare practitioners. Am J Managed Care. 1997;3:1884-1906.
2. Bauman JL. Antiarrhythmic drugs. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data. 9th ed. Stamford, CT: Appleton & Lange; 1999.
3. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996.
4. Skanes AC, Green MS. What have clinical trials taught us about proarrhythmias? Can J Cardiol. 1996;12(suppl B):20B-26B.
5. Doig JC. Drug-induced cardiac arrhythmias. Drug Safety. 1997;17(4):265-275.
6. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994;331:785-791.
7. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Eng J Med. 1991;324:781-788.
8. Green HC, Roden DM, Katz RJ, et al. The Cardiac Arrhythmia Suppression Trial: First Cast . . . then Cast II. Am Coll Cardiol. 1992;19:894-898.
9. Waldo AC, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7-12.
10. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: Types, risks and management. Am J Cardiol. 1997;80(A):82G-89G.
11. Chase S. Antiarrhythmics. RN. 1997:(May):41-48.
12. Caron J, Libersa C. Adverse effects of class I antiarrhythmic drugs. Drug Safety. 1997;17(1):8-36.
13. Campbell TJ, Williams KM. Therapeutic drug monitoring: Antiarrhythmic drugs. Br J Clin Pharmacol. 1998; 46:307-319.
14. Grace AA, Camm AJ. Quinidine. N Engl J Med. 1998; 338:35-45.
15. Romankiewicz JA, Reidenberg M, Drayer D, et al. The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: An approach to control quinidine-induced diarrhea. Am Heart J. 1978;96:518-520.
16. RuDusky BM, Barre W. Treatment of quinidine-induced diarrhea: Implications for enhanced control of atrial fibrillation in the geriatric population. JAGS. 1998;46:932.
17. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: A systemic review of published case reports. Ann Intern Med. 1998;129:886-890.
18. Adult advanced cardiac life support. JAMA. 1992;268: 2199-2141.
19. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994;20:61-86.
20. Campbell RWF. Mexiletine. N Engl J Med. 1987;316: 29-34.
21. Oskarsson P, Ljunggren JG, Lins PE, et al. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care. 1997;20:1594-1598.
22. Roden DM, Woosley RL. Tocainide. N Engl J Med. 1986;315:41-45.
23. Roden DM, Woosley RL. Flecainide. N Engl J Med. 1986;315:36-41.
24. Funck-Brentano C, Kroemer HK, Roden DM. Propafenone. N Engl J Med. 1990;322:518-525.
25. Bauman JL. Class III antiarrhythmic agents: The next wave. Pharmacotherapy. 1997;17:76S-83S.
26. Hilleman D, Miller MA, Parker R, et al. Optimal management of amiodarone therapy: Efficacy and side effects. Pharmacotherapy. 1998;18:138S-145S.
27. Murphy MT, Wilkoff BL. What internists should know about amiodarone. Cleve Clin J Med. 1998;65(3):159-166.
28. Swanton H. Amiodarone. Br J Hosp Med. 1997;58(7): 329-332.
29. Jafari-Fesharaki M, Scheinman MM. Adverse effects of amiodarone. Pacing Clin Electrophysiol. 1998;21:108-120.
30. Li-Saw-Hee FL, Lip GYH. Digoxin revisited. Q J Med. 1998;91:259-264.
31. Gomez MN. Magnesium and cardiovascular disease. Anesthesiology. 1998;89:222-240.
32. Vaughan-Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129-147.